Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
SUPN - Supernus Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$60.00
DETAILS
HIGH:
$65.00
LOW:
$55.00
MEDIAN:
$60.00
CONSENSUS:
$60.00
UPSIDE:
24.46%
Stock News
What to Know About This Fund’s Sale of a Pharma Stock Up 56% in a Year
Supernus Pharmaceuticals delivers specialty therapies for CNS disorders, targeting healthcare providers and specialty pharmacies nationwide.
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
ROCKVILLE, Md. , May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Bank of America 2026 Health Care Conference on Tuesday, May 12, 2026, at 3:40 p.
Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference
ROCKVILLE, Md., May 06, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Bank of America 2026 Health Care Conference on Tuesday, May 12, 2026, at 3:40 p.m. PT (6:40 p.m. ET) at the Encore Hotel in Las Vegas, NV.
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript
Supernus (SUPN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.42 per share a year ago.
Supernus Announces First Quarter 2026 Financial Results
ROCKVILLE, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the first quarter 2026 and associated Company developments.
Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs
Biogen beats Q1 earnings and revenue estimates, fueled by new drug growth, but cuts 2026 EPS outlook to reflect M&A costs.
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report first quarter 2026 financial and business results after the market closes on Tuesday, May 5, 2026.
Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Acquired Rep. Gilbert Ray Cisneros, Jr.
Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Supernus Pharmaceuticals stock on March 3rd. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account. Representative
Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Cross Above 200-Day Moving Average – Should You Sell?
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN - Get Free Report)'s share price crossed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $49.66 and traded as high as $51.06. Supernus Pharmaceuticals shares last traded at $50.96, with a volume of 873,941 shares. Analysts Set
Supernus Pharmaceuticals, Inc. $SUPN Stock Holdings Lowered by JPMorgan Chase & Co.
JPMorgan Chase and Co. trimmed its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) by 45.6% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 171,285 shares of the specialty pharmaceutical company's stock after selling 143,816 shares during the period. JPMorgan Chase
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Receives $62.17 Consensus PT from Brokerages
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN - Get Free Report) has received a consensus rating of "Hold" from the seven brokerages that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The
Supernus Pharma Insider Sells $5.4 Million as Stock Surges 53% in a Year
A Supernus Pharmaceuticals executive reported the sale of 107,250 Common Stock shares over three days for a total value of about $5.4 million. Bhatt reported holding 17,044 shares of directly owned common stock after the transactions.
Frederick Hudson Sells 5,369 Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) Stock
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN - Get Free Report) Director Frederick Hudson sold 5,369 shares of the business's stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $50.61, for a total transaction of $271,725.09. Following the completion of the sale, the director directly owned 60,413 shares in the
Supernus Pharmaceuticals, Inc. (SUPN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Supernus Pharmaceuticals, Inc. (SUPN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Victory Capital Management Inc.
Victory Capital Management Inc. decreased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) by 25.5% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 559,835 shares of the specialty pharmaceutical company's stock after selling 191,708 shares during the quarter.
American Century Companies Inc. Decreases Position in Supernus Pharmaceuticals, Inc. $SUPN
American Century Companies Inc. trimmed its stake in Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) by 44.4% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 509,368 shares of the specialty pharmaceutical company's stock after selling 406,786 shares during the period. American Century Companies
Bethany Sensenig Sells 4,475 Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) Stock
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN - Get Free Report) Director Bethany Sensenig sold 4,475 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $51.01, for a total value of $228,269.75. The sale was disclosed in a legal filing with the SEC, which can be
Price Targets
Supernus Pharmaceuticals (SUPN) PT Raised to $65 at TD Cowen
$65.00
(was $57.58)
Craig-Hallum
Supernus price target raised to $55 from $50 at Stifel
$55.00
(was $49.28)
Annabel Samimy
·
Stifel Nicolaus
Supernus upgraded to Overweight from Neutral at Piper Sandler
$65.00
(was $48.00)
Piper Sandler
Supernus price target raised to $63 from $46 at Cantor Fitzgerald
$63.00
(was $47.41)
Cantor Fitzgerald
Supernus price target raised to $40 from $36 at Piper Sandler
$40.00
(was $45.12)
Piper Sandler
Supernus upgraded to Overweight from Neutral at Cantor Fitzgerald
$42.00
(was $33.45)
Cantor Fitzgerald
Piper downgrades Supernus to Neutral on slower Qelbree growth
$36.00
(was $33.49)
David Amsellem
·
Piper Sandler
Piper Sandler Reiterates Overweight Rating on Supernus Pharmaceuticals (SUPN)
$41.00
(was $27.84)
David Amsellem
·
Piper Sandler
Jefferies on Supernus (SUPN): 'We expect a -5-10% stock reaction after the FDA's rejection of SPN-830'
$40.00
(was $32.27)
Irene Buhalo
·
Jefferies
Stifel on Supernus Pharmaceuticals (SUPN): 'SPN-830 Approval Delayed Again, but Near-Term Impact Relatively Minor'
$38.00
(was $32.27)
Annabel Samimy
·
Stifel Nicolaus